Effects of 14 frequently used drugs on prostate-specific antigen expression in prostate cancer LNCaP cells

Iguchi, Kazuhiro; Hashimoto, Mitsuru; Kubota, Masafumi; Yamashita, Shuji; Nakamura, Mitsuhiro; Usui, Shigeyuki; Sugiyama, Tadashi; Hirano, Kazuyuki

doi:10.3892/ol.2014.1936

Cited by 6 publications

(5 citation statements)

References 11 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…37 In addition to increased testosterone concentrations, decreased BMI, IR, and HbA 1c , 38,39 some other factors can also influence PSA changes: older age, recent ejaculation, certain medications (statin and betamethasone). [40][41][42] We observed no cases of PCa.…”

Section: Discussionmentioning

confidence: 54%

Effects of Testosterone Therapy on Erythrocytosis and Prostate Adverse Events in Obese Males with Functional Hypogonadism and Type 2 Diabetes in a 2-Year Clinical Trial

Antonič

Antonič²,

Pfeifer

2020

Androgens: Clinical Research and Therapeutics

View full text Add to dashboard Cite

Aims: Testosterone therapy (TTh) has been postulated to increase the risk of prostate adverse events (PAEs) and erythrocytosis, risk further exacerbated in high-risk obese patients with type 2 diabetes (T2D) and functional hypogonadism (FH). We investigated safety aspects of TTh in obese males with FH and T2D by observing the incidence of PAEs and erythrocytosis and determining when statistically significant difference from the baseline manifests in hematocrit (Hct) and prostate-specific antigen (PSA) levels. Materials and Methods: Fifty-five obese Caucasian men with FH and T2D participated in a two-part prospective observational clinical study (first year: double-blind randomized placebo-controlled trial employing testosterone undecanoate; second year: open-label follow-up with all participants receiving TTh). Outcomes were assessments of Hct and PSA levels at the baseline, and 3, 6, and 12 months into each of 2 years of the study. Results: No adverse cardiovascular events or PAEs were observed. Hct first increased at statistically significant level from the baseline after 3 months of TTh in group T and after 6 months of TTh in group P. Individual Hct values for all participants remained <0.52 throughout 2-year course of the study. PSA increased from the baseline in both groups within 3-6 months of trial start regardless of intervention applied (placebo or TTh). Fifty-two patients never exceeded PSA level of 4.0 lg/L nor experienced year-on-year PSA increase >1.4 lg/L. No subject ever reached supraphysiological concentration of total testosterone. Conclusions: Our results show that TTh may be safe in obese males with FH and T2D. ClinicalTrials.gov ID: NCT0379232.

show abstract

Section: Discussionmentioning

confidence: 54%

Effects of Testosterone Therapy on Erythrocytosis and Prostate Adverse Events in Obese Males with Functional Hypogonadism and Type 2 Diabetes in a 2-Year Clinical Trial

Antonič

Antonič²,

Pfeifer

2020

Androgens: Clinical Research and Therapeutics

View full text Add to dashboard Cite

show abstract

“…Moreover, a recent study suggested that obese men have lower PSA levels, as compared to normal weight men, possibly due to hormonal changes especially by an elevated E2/testosterone ratio and hemodilution [ 44 ]. Furthermore, PSA levels are influenced by a number of drugs, such as non-steroidal anti-inflammatory drugs, statins and thiazide diuretics [ 45 , 46 ].…”

Section: Discussionmentioning

confidence: 99%

An Ultra-Rapid Biosensory Point-of-Care (POC) Assay for Prostate-Specific Antigen (PSA) Detection in Human Serum

Mavrikou

Moschopoulou

Zafeirakis³

et al. 2018

Sensors

View full text Add to dashboard Cite

Prostate-specific antigen (PSA) is the established routine screening tool for the detection of early-stage prostate cancer. Given the laboratory-centric nature of the process, the development of a portable, ultra rapid high-throughput system for PSA screening is highly desirable. In this study, an advancedpoint-of-care system for PSA detection in human serum was developed based on a cellular biosensor where the cell membrane was modified by electroinserting a specific antibody against PSA. Thirty nine human serum samples were used for validation of this biosensory system for PSA detection. Samples were analyzed in parallel with a standard immunoradiometric assay (IRMA) and an established electrochemical immunoassay was used for comparison purposes. They were classified in three different PSA concentration ranges (0, <4 and ≥4 ng/mL). Cells membrane-engineered with 0.25 μg/mL anti-PSA antibody demonstrated a statistically lower response against the upper (≥4 ng/mL) PSA concentration range. In addition, the cell-based biosensor performed better than the immunosensor in terms of sensitivity and resolution against positive samples containing <4 ng/mL PSA. In spite of its preliminary, proof-of-concept stage of development, the cell-based biosensor could be used as aninitiative for the development of a fast, low-cost, and high-throughput POC screening system for PSA.

show abstract

“…PSA is a widely used biomarker for PCa and has been recommended as a tool for the screening of PCa and as a follow-up marker for PCa therapy. A study investigating the effects of 14 commonly prescribed drugs on the expression of PSA mRNA in PCa cells (LNCaP cells) showed that except for a positive effect of betamethasone, all other drugs including metformin and insulin did not significantly affect PSA expression [ 66 ]. A later study using LNCaP cells also did not find an effect of metformin on PSA [ 67 ].…”

Section: Prostate-related Healthmentioning

confidence: 99%

The Effect of Metformin on Male Reproductive Function and Prostate: An Updated Review

Tseng

2022

World J Mens Health

View full text Add to dashboard Cite

Metformin is the first-line oral antidiabetic drug that shows multiple pleiotropic effects of anti-inflamation, anti-cancer, anti-aging, anti-microbia, anti-atherosclerosis, and immune modulation. Metformin's effects on men's related health are reviewed here, focusing on reproductive health under subtitles of erectile dysfunction (ED), steroidogenesis and spermatogenesis; and on prostate-related health under subtitles of prostate specific antigen (PSA), prostatitis, benign prostate hyperplasia (BPH), and prostate cancer (PCa). Updated literature suggests a potential role of metformin on arteriogenic ED but controversial and contradictory effects (either protective or harmful) on testicular functions of testosterone synthesis and spermatogenesis. With regards to prostate-related health, metformin use may be associated with lower levels of PSA in humans, but its clinical implications require more research. Although there is a lack of research on metform's effect on prostatitis, it may have potential benefits through its anti-microbial and anti-inflammatory properties. Metformin may reduce the risk of BPH by inhibiting the insulin-like growth factor 1 pathway and some but not all studies suggest a protective role of metformin on the risk of PCa. Many clinical trials are being conducted to investigate the use of metformin as an adjuvant therapy for PCa but results currently available are not conclusive. While some trials suggest a benefit in reducing the metastasis and recurrence of PCa, others do not show any benefit. More research works are warranted to illuminate the potential usefulness of metformin in the promotion of men's health.

show abstract

Effects of 14 frequently used drugs on prostate-specific antigen expression in prostate cancer LNCaP cells

Cited by 6 publications

References 11 publications

Effects of Testosterone Therapy on Erythrocytosis and Prostate Adverse Events in Obese Males with Functional Hypogonadism and Type 2 Diabetes in a 2-Year Clinical Trial

Effects of Testosterone Therapy on Erythrocytosis and Prostate Adverse Events in Obese Males with Functional Hypogonadism and Type 2 Diabetes in a 2-Year Clinical Trial

An Ultra-Rapid Biosensory Point-of-Care (POC) Assay for Prostate-Specific Antigen (PSA) Detection in Human Serum

The Effect of Metformin on Male Reproductive Function and Prostate: An Updated Review

Contact Info

Product

Resources

About